✦ LIBER ✦

Active immunotherapy of human solid tumor with autologous cells treated with cholesteryl hemisuccinate a phase I study

✍ Scribed by Yehuda G. Skornick; Guo H. Rong; William F. Sindelar; Lysiane Richert; Joseph M. Klausner; Ronald R. Rozin; Meir Shinitzky

Publisher: John Wiley and Sons
Year: 1986
Tongue: English
Weight: 504 KB
Volume: 58
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19860801)58:3<650::aid-cncr2820580309>3.0.co;2-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Active specific immunotherapy with tumor

Active specific immunotherapy with tumor cells and Corynebacterium parvum. A phase I study

✍ Craig S. McCune; W. Bradford Patterson; Edgar C. Henshaw 📂 Article 📅 1979 🏛 John Wiley and Sons 🌐 English ⚖ 617 KB

Phase I study of the adoptive immunother

Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells

✍ Amitabha Mazumder; Timothy J. Eberlein; Elizabeth A. Grimm; Debra J. Wilson; And 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 977 KB

A phase I study of autologous dendritic

A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer

✍ Yukio Iwashita; Kouichirou Tahara; Shigeru Goto; Atsushi Sasaki; Seiichiro Kai; 📂 Article 📅 2003 🏛 Springer-Verlag 🌐 English ⚖ 298 KB

Phase I study of high-dose thiotepa with

Phase I study of high-dose thiotepa with busulfan, etoposide, and autologous stem cell support in children with disseminated solid tumors

✍ Pession, Andrea; Prete, Arcangelo; Locatelli, Franco; Bella, Santiago; Melchiond 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB 👁 2 views

Background. The aim of this phase I study was to define the maximum tolerated dose (MTD) of thiotepa (TT), administered with busulfan (BU) 480 mg/m 2 and etoposide 2,400 mg/m 2 , followed by autologous bone marrow transplantation (ABMT) or peripheral blood stem cell transplantation (APBSCT) support

Phase I study to the immunotherapy of me

Phase I study to the immunotherapy of metastatic malignant melanoma by a cancer vaccine consisting of autologous cancer cells transfected with the human IL-2 gene

✍ G. Stingl; E.-B. Bröcker; R. Mertelsmann; K. Wolff; S. Schreiber; E. Kämpgen; A. 📂 Article 📅 1997 🏛 Springer 🌐 English ⚖ 52 KB

Immunotherapy in high-risk chemotherapy-

Immunotherapy in high-risk chemotherapy-resistant patients with metastatic solid tumors and hematological malignancies using intentionally mismatched donor lymphocytes activated with rIL-2: a phase I study

✍ Shimon Slavin; Aliza Ackerstein; Reuven Or; Michael Y. Shapira; Benjamin Gesundh 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 287 KB